Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gilead’s John C. Martin: One Breakthrough Drug After Another

In his 25-year-tenure at Gilead, first as research chief and then as the boss, Martin led the development of the most widely prescribed HIV pill and, last year, a treatment for the liver virus hepatitis C that can cure 90% of patients and generated $12 billion in revenue in its first year on the market. It […]

Read More »

JDRF Announces $1.8 Million Two-year Partnership with Lilly to Provide Support for Newly-diagnosed Families with Diabetes

NEW YORK, May 6, 2015 /PRNewswire-USNewswire/ — JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Eli Lilly and Company, a global leader in diabetes care announced a two-year partnership that will provide $1.8 Million in support of JDRF’s mission to improving the lives of people with T1D. This agreement provides a variety of programs and […]

Read More »

GSK sees little prospect of U.S. generic Advair in 2016

A logo of GlaxoSmithKline Pharmaceuticals Ltd company is pictured outside its headquarters in Mumbai December 16, 2013. Reuters/Danish Siddiqui (Reuters) – After relying for years on its top-selling lung drug Advair, GlaxoSmithKline is now braced for the worst in the form of cheap generics – but not just yet. Chief Executive Andrew Witty said on […]

Read More »

Alexion Pharma to buy Synageva BioPharma for $8.4 billion

(Reuters) – Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to boost its rare drug pipeline. Alexion’s cash-and-stock offer values Synageva at $225.92 per share — more than double of Synageva closing price of $95.87 on Tuesday. Synageva’s shares were trading at $216 before the bell on Wednesday, while […]

Read More »

GlaxoSmithKline targets growth across units, scraps ViiV IPO

May 6 (Reuters) – GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook. Chief Executive Andrew Witty is under […]

Read More »

Two Under-the-Radar Updates Pfizer (PFE) Investors Need to Know About

Drugmaking behemoth Pfizer Inc. (PFE) had some important information hidden in between the layers Of its first quarter conference call, said a columnist at The Motley Fool on Wednesday, and investors would be wise to take a closer look before parsing out the company’s value. Pfizer had two major updates that could significantly impact its […]

Read More »

8 out of 10 Medical Device Companies Expect Medium or High Levels of Market Competition, According to Recent Survey from Cutting Edge Information

RESEARCH TRIANGLE PARK, NC–(Marketwired – May 05, 2015) – Medical device manufacturers face increasing competition as they move products through development and into a saturated market. According to a new report by primary intelligence provider Cutting Edge Information, 80% of surveyed medical device companies expect medium or high levels of market competition.  Nearly half (49%) of […]

Read More »

Isis Reports Financial Results and Highlights for First Quarter 2015

CARLSBAD, Calif., May 5, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014.  Isis’ significantly improved financial results were due to higher […]

Read More »

OPKO Health Acquires EirGen Pharma

MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than […]

Read More »

Transparency Is Still A Problem As Big Pharma Struggles With Its Image

“Reputation, built on our past, shapes our present and future. A good reputation can open many doors; a bad reputation can close many more. A good reputation generates respect. A bad reputation breeds suspicion.” Those are not the words of a business consultant or from a television talk show host like Dr. Phil. They are […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom